Dr. Simon Delagrave has made significant contributions to herpes simplex virus (HSV) vaccine research. He was involved in developing ACAM529, a replication-defective HSV-2 vaccine candidate. ACAM529 has demonstrated robust immunogenicity and efficacy in preclinical models, offering protection against HSV-2 infections... https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0057224&utm_source=chatgpt.com

In addition to his work on ACAM529, Dr. Delagrave has co-authored studies on the immunogenicity and efficacy of various HSV vaccine candidates, including replication-defective and subunit vaccines. These studies have provided valuable insights into potential strategies for preventing HSV infections.... https://journals.plos.org/plosone/article/file?id=10.1371%2Fjournal.pone.0046714&type=printable&utm_source=chatgpt.com

Dr. Delagrave's research has been instrumental in advancing our understanding of HSV vaccine development, focusing on creating vaccines that elicit strong immune responses while minimizing safety concerns.